{"id":"W4386915712","doi":"10.1200/jco.23.01423","title":"Progression-Free Survival Should Not Be Used as a Primary End Point for Registration of Anticancer Drugs","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":69,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Queen's University","funders":"","keywords":"Medicine; Clinical endpoint; Anticancer drug; Oncology; End point; Progression-free survival; Overall survival; Internal medicine; Pharmacology; Drug; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":["metaresearch"],"domain":"methods","study_design":"theoretical_or_conceptual","genre":"commentary","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"},{"model":"gpt","categories":["metaresearch"],"domain":"evaluation","study_design":"theoretical_or_conceptual","genre":"commentary","about_ca_system":false,"about_ca_topic":false,"confidence":"high","status":"direct model label, unvalidated"}],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.03641511,0.0006281817,0.003153891,0.00194534,0.0008788087,0.003360082,0.001462059,0.002853525,0.004407579],"category_scores_gemma":[0.1044517,0.0004165199,0.002776555,0.002388744,0.0009952532,0.002946406,0.001052933,0.005579063,0.002658846],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001941727,"about_ca_system_score_gemma":0.003089276,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00280982,"about_ca_topic_score_gemma":0.004291391,"domain_scores_codex":[0.965863,0.02050985,0.005262219,0.001709797,0.005796545,0.000858512],"domain_scores_gemma":[0.9085665,0.05410843,0.01224765,0.008877006,0.01388157,0.002318799],"domain_codex":null,"domain_gemma":"methods","domain_candidate":"methods","domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.01930535,0.0009187345,0.1654357,0.004421171,0.004264688,0.0007886754,0.0005356544,0.004890776,0.00173052,0.0395474,0.2271116,0.5310498],"study_design_scores_gemma":[0.00372745,0.008959499,0.4541625,0.005810949,0.004762177,0.004218726,0.0007616681,0.03643856,0.01027475,0.1268705,0.3434799,0.0005333828],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"commentary","genre_scores_codex":[0.3803413,0.06851374,0.08438978,0.2067429,0.02801024,0.001878969,0.04558907,0.001452678,0.1830814],"genre_scores_gemma":[0.9182097,0.006248239,0.01931315,0.0274535,0.00543056,0.0009516882,0.01087172,0.0002779234,0.01124345],"genre_candidate":"commentary","genre_consensus":null,"teacher_disagreement_score":0.9635849,"threshold_uncertainty_score":0.1925839,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.7421747698617622,"score_gpt":0.6165159011575854,"score_spread":0.1256588687041769,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}